(Motley Fool)–NuVasive has high hopes for 2019. New CEO Christopher Barry described it, “We will demonstrate a disciplined approach toward funding key areas for long-term company growth — furthering our product leadership in global implant systems, accelerating our surgical intelligence platform, and investing in surgeon training and education with an ongoing focus on globalization efforts.”
Some investors probably won’t like the guidance that NuVasive gave. The company believes that revenue for 2019 will come in between $1.14 billion and $1.16 billion, which is a bit below the $1.17 billion consensus forecast among those following the stock. Similarly, adjusted earnings guidance for $2.20 to $2.30 per share would be well below the $2.47 that investors project NuVasive will be able to earn.
Shareholders will want to pay close attention to how the company’s innovations perform. For instance, the spinal surgery specialist just announced an all-internal bone transport system to treat bone defects in the tibia and femur. If NuVasive can take its spinal expertise and extend it to other applications, the long-term growth implications could be huge — and encouraging for investors, as long as NuVasive remains independent.
Read Complete Article:https://www.fool.com/investing/2019/02/20/nuvasive-overcomes-industry-headwinds-to-finish-20.aspx